| Update on clinical researches on novel antibiotics against Gram-negative bacteria |
| Received:June 23, 2023 Revised:August 03, 2023 Click here to download the full text |
| Citation of this paper:YAO Yumeng,CHEN Zhangzhang,SHAN Yuzhang,PAN Jue,HU Bijie.Update on clinical researches on novel antibiotics against Gram-negative bacteria[J].Chinese Journal of Clinical Medicine,2024,31(1):133-142 |
| Hits: 364 |
| Download times: 119 |
| Author Name | Affiliation | E-mail | | YAO Yumeng | Department of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHEN Zhangzhang | Department of Pharmacology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | SHAN Yuzhang | Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | PAN Jue | Department of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | HU Bijie | Department of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Department of Infection Control and Management, Zhongshan Hospital, Fudan University, Shanghai 200032, China | hu.bijie@zs-hospital.sh.cn |
|
| Abstract:Therapeutic options are limited for drug-resistant Gram-negative bacterial (GNB) infections, posing great threats to human health. Major pathogens include extended-spectrum β-lactamases or AmpC β-lactamases and carbapenem-resistant bacteria. Among them, carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae are the most difficult to be treated. In recent years, a variety of novel antibiotics with anti-GNB activity have been developed in the world. In this paper, ten novel antibiotics are reviewed, including temocillin, cefiderocol, ceftolozone/tazobactam, ceftazidime/avibactam, cefepime/enmetazobactam, meropenem/vaborbactam, imipenem-cilastatin/relebactam, aztreonam/avibactam, eravacycline and plazomicin. Their mechanisms of action, antibacterial spectrum and potential side effects were introduced. Combined with the latest clinical studies of hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP), intra-abdominal infection (IAI) and complicated urinary tract infection (cUTI), the indications and potential clinical applications are summarized. |
| keywords:Gram-negative bacteria antibiotic resistance carbapenem |
| HTML View Full Text View/Add Comment Download reader |
|
|
|